Literature DB >> 7543872

Induction of feline immunodeficiency virus-specific cell-mediated and humoral immune responses following immunization with a multiple antigenic peptide from the envelope V3 domain.

J N Flynn1, C A Cannon, G Reid, M A Rigby, J C Neil, O Jarrett.   

Abstract

Cytotoxic T-cell determinants should be an important component of a vaccine against feline immunodeficiency virus (FIV). Epitope mapping studies have revealed an immunodominant neutralization epitope within the third variable (V3) domain of the viral envelope glycoprotein comprizing 17 amino acids (residues 390-406: RAISSWKQRNRWEWRPD). We have investigated the induction of FIV-specific cytotoxicity and anti-peptide antibody in cats immunized with a multiple antigenic peptide (MAP) containing this epitope. Virus-specific lymphocytotoxicity was determined using autologous or allogeneic skin fibroblasts as target cells labelled with chromium-51 and pulsed with overlapping 10 amino acid peptides. Cytotoxic effector cells derived from fresh peripheral blood were detected in five out of 10 immunized cats. The cell-mediated immune response appeared to be directed to envelope peptide 1 (RAISSWKQRN) and peptide 2 (SWKQRNRWEW), with recognition of peptide 3 (QRNRWEWRPD) in only one cat. An antibody response to the 17 amino acid peptide immunogen was detected in seven immunized cats, which was directed to envelope peptides 2 and 3. These results suggest that different epitopes may be recognized by the cell-mediated and humoral immune responses. None of the cats was protected from challenge with the Glasgow8 isolate of FIV (FIV/GL-8). This study has implications for vaccine strategies using synthetic peptides to induce virus-specific cell-mediated immune responses.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543872      PMCID: PMC1383877     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  24 in total

1.  Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route.

Authors:  A M Mowat; A M Donachie; G Reid; O Jarrett
Journal:  Immunology       Date:  1991-03       Impact factor: 7.397

2.  Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide.

Authors:  W M Kast; L Roux; J Curren; H J Blom; A C Voordouw; R H Meloen; D Kolakofsky; C J Melief
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

3.  Peptide-induced antiviral protection by cytotoxic T cells.

Authors:  M Schulz; R M Zinkernagel; H Hengartner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

4.  HIV revealed: toward a natural history of the infection.

Authors:  D Baltimore; M B Feinberg
Journal:  N Engl J Med       Date:  1989-12-14       Impact factor: 91.245

5.  Priming of influenza virus-specific cytotoxic T lymphocytes vivo by short synthetic peptides.

Authors:  X M Gao; B Zheng; F Y Liew; S Brett; J Tite
Journal:  J Immunol       Date:  1991-11-15       Impact factor: 5.422

6.  Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs.

Authors:  H Takahashi; T Takeshita; B Morein; S Putney; R N Germain; J A Berzofsky
Journal:  Nature       Date:  1990-04-26       Impact factor: 49.962

7.  Safety and immunogenicity of a V3 loop synthetic peptide conjugated to purified protein derivative in HIV-seronegative volunteers.

Authors:  A Rubinstein; H Goldstein; M Pettoello-Mantovani; Y Mizrachi; B R Bloom; E Furer; B Althaus; J U Que; T Hasler; S J Cryz
Journal:  AIDS       Date:  1995-03       Impact factor: 4.177

8.  Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

Authors:  K Javaherian; A J Langlois; C McDanal; K L Ross; L I Eckler; C L Jellis; A T Profy; J R Rusche; D P Bolognesi; S D Putney
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

9.  Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome.

Authors:  N C Pedersen; E W Ho; M L Brown; J K Yamamoto
Journal:  Science       Date:  1987-02-13       Impact factor: 47.728

10.  Antiviral cytotoxic T cell response induced by in vivo priming with a free synthetic peptide.

Authors:  P Aichele; H Hengartner; R M Zinkernagel; M Schulz
Journal:  J Exp Med       Date:  1990-05-01       Impact factor: 14.307

View more
  10 in total

1.  Vaccination with a feline immunodeficiency virus multiepitopic peptide induces cell-mediated and humoral immune responses in cats, but does not confer protection.

Authors:  J N Flynn; C A Cannon; J C Neil; O Jarrett
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

2.  Sequential CD134-CXCR4 interactions in feline immunodeficiency virus (FIV): soluble CD134 activates FIV Env for CXCR4-dependent entry and reveals a cryptic neutralization epitope.

Authors:  Aymeric de Parseval; Chris K Grant; K Jagannadha Sastry; John H Elder
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

3.  Feline immunodeficiency virus vaccination: characterization of the immune correlates of protection.

Authors:  M J Hosie; J N Flynn
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif.

Authors:  C M Leutenegger; F S Boretti; C N Mislin; J N Flynn; M Schroff; A Habel; C Junghans; S A Koenig-Merediz; B Sigrist; A Aubert; N C Pedersen; B Wittig; H Lutz
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

5.  A longitudinal study of feline immunodeficiency virus-specific cytotoxic T lymphocytes in experimentally infected cats, using antigen-specific induction.

Authors:  J A Beatty; B J Willett; E A Gault; O Jarrett
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

6.  Feline leukaemia virus: protective immunity is mediated by virus-specific cytotoxic T lymphocytes.

Authors:  J N Flynn; L Hanlon; O Jarrett
Journal:  Immunology       Date:  2000-09       Impact factor: 7.397

7.  DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies.

Authors:  M J Hosie; J N Flynn; M A Rigby; C Cannon; T Dunsford; N A Mackay; D Argyle; B J Willett; T Miyazawa; D E Onions; O Jarrett; J C Neil
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

Review 8.  Molecular epidemiology of feline immunodeficiency virus in the domestic cat (Felis catus).

Authors:  Jessica J Hayward; Allen G Rodrigo
Journal:  Vet Immunol Immunopathol       Date:  2009-10-14       Impact factor: 2.046

9.  Ramified feline microglia selects for distinct variants of feline immunodeficiency virus during early central nervous system infection.

Authors:  Andreas Hein; Holger Schuh; Simone Thiel; Jean-Pierre Martin; Rüdiger Dörries
Journal:  J Neurovirol       Date:  2003-08       Impact factor: 2.643

10.  Recombination in feline immunodeficiency virus from feral and companion domestic cats.

Authors:  Jessica J Hayward; Allen G Rodrigo
Journal:  Virol J       Date:  2008-06-17       Impact factor: 4.099

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.